# A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)

> **NCT00827918** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 216 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MK-8998
- **DRUG:** Comparator: Olanzapine
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00827918
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2015-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00827918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00827918, "A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00827918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*